Gleason Score Explained: What Your Biopsy Report Means

A Gleason score is the single number on your prostate biopsy report that decides almost everything that happens next — whether you watch, treat, or panic. And yet most men leave the consultation knowing the number but not what it means. I have sat across from patients who were told they had “Gleason 7” and assumed it was a near-death sentence, when in fact their cancer was one of the most treatable forms of prostate cancer that exists. I have also sat across from men told the same “Gleason 7” who needed surgery scheduled within weeks. Same number. Two very different cancers. This guide explains why — and translates every line of your biopsy report into the language your urologist is actually using. If you have just received a prostate biopsy result, or you are about to, read this before your follow-up. For the wider context, see our full Prostate Health Hub.

What a Gleason Score Actually Measures

The Gleason score grades how abnormal your prostate cancer cells look under the microscope — specifically, how disorganized the glandular architecture has become. Normal prostate tissue forms neat, recognizable gland structures. Cancer disrupts that architecture in predictable, gradable ways. Pathologist Dr. Donald Gleason developed the system in the 1960s, and despite multiple revisions since, the core principle holds: the more chaotic the gland architecture, the more aggressive the cancer behaves clinically[1].

The pathologist looks at your biopsy cores under a microscope and identifies Gleason “patterns” — graded 1 through 5. In modern practice, Patterns 1 and 2 are essentially never reported, because what they describe is no longer considered cancer. Pattern 3 is the lowest grade you will see on a real biopsy report. Pattern 4 means the glands are fusing, becoming cribriform (sieve-like), or losing their lumens. Pattern 5 means the architecture has collapsed — sheets of cells, individual cells infiltrating tissue, no gland formation at all[2].

Your Gleason score is the sum of two numbers: the most common pattern in your biopsy, plus the second-most common. So a report that reads “Gleason 3+4=7” means Pattern 3 was the dominant finding, with Pattern 4 as the secondary finding. The minimum modern score is 3+3=6. The maximum is 5+5=10. Anything you read online from before 2005 that mentions “Gleason 4” or “Gleason 5” as a diagnosis is outdated — those low scores stopped being assigned to cancer over twenty years ago[3].

The Three Patterns You Will See on Your Report

Pattern 3 is the most common finding in early-detected prostate cancer. The cancer glands are still discrete and individually recognizable, with visible lumens (the hollow center of each gland). They vary in size and shape, but they look like glands. Pattern 3 cancer rarely spreads beyond the prostate, almost never invades the lymph nodes, and is the reason active surveillance has become a mainstream first-line management option[4].

Pattern 4 is where the biology shifts. The glands fuse into each other, form cribriform (Swiss-cheese) patterns, or become glomeruloid (resembling a glomerulus in the kidney). Some glands lose their lumens entirely. This is the threshold pattern — the presence of Pattern 4 in any meaningful percentage is what separates cancers that we tend to watch from cancers we tend to treat. Within Pattern 4, the cribriform subtype is particularly aggressive and recent guidelines recommend it be specifically named on pathology reports[5].

Pattern 5 is the most disorganized form. There are no glands left to grade — instead, the pathologist sees solid sheets of cancer cells, single cells infiltrating tissue, or comedo necrosis (dead cancer cells at the center of cell clusters). Pattern 5 is the prognostic alarm bell. Even when present as a minor component, it changes management.

The ISUP Grade Group: What Your Urologist Actually Uses

Here is where most online explanations stop being useful. The raw Gleason score (6, 7, 8, 9, 10) hides a problem: a Gleason 3+4=7 and a Gleason 4+3=7 add up to the same number but behave very differently. To fix this, the International Society of Urological Pathology (ISUP) introduced the Grade Group system in 2014, now endorsed by both the World Health Organization and the AUA[6].

The five Grade Groups translate Gleason into a more honest clinical tier:

• Grade Group 1 — Gleason ≤6. Very low-risk cancer. Almost never spreads. Active surveillance is the default management.
• Grade Group 2 — Gleason 3+4=7. Pattern 3 dominant. Most are still appropriate for active surveillance in selected men.
• Grade Group 3 — Gleason 4+3=7. Pattern 4 dominant. Treatment is usually recommended.
• Grade Group 4 — Gleason 8 (4+4, 3+5, or 5+3). High-risk cancer. Definitive treatment is the standard.
• Grade Group 5 — Gleason 9 or 10 (4+5, 5+4, 5+5). Very high-risk. Multimodal treatment — surgery or radiation plus hormonal therapy — is typical.

When you sit down with your urologist, ask for your Grade Group, not just your Gleason. The Grade Group is the number that drives every decision tree in modern guidelines, including the AUA/ASTRO/SUO 2024 prostate cancer guideline that informs US-based treatment recommendations[7].

Why 3+4 and 4+3 Are Different Cancers

This is the single most misunderstood point in patient-facing prostate cancer information. Both 3+4=7 and 4+3=7 sum to 7. They are not the same cancer.

In 3+4=7 (Grade Group 2), Pattern 3 occupies the majority of the cancer — often 60–80% — and Pattern 4 the rest. The cancer is still architecturally well-differentiated overall, with a minority aggressive component. In 4+3=7 (Grade Group 3), those proportions flip: the majority is Pattern 4, with a smaller well-differentiated Pattern 3 component. The amount of Pattern 4 — the actual percentage — is the strongest single predictor of how the cancer behaves[8].

A large cohort study following men after radical prostatectomy found that 4+3=7 cancers carried roughly double the risk of biochemical recurrence at five years compared with 3+4=7 cancers, even after adjusting for PSA and stage[9]. That is the same number on the report, but a meaningfully different cancer. Modern reports should also tell you the percentage of Pattern 4 within a Grade Group 2 or 3 result, because that percentage refines the risk further. Ask for it if it is not stated.

Tertiary Pattern 5: The Detail That Quietly Changes Prognosis

Sometimes a pathologist sees three patterns in a single biopsy — the dominant pattern, the secondary pattern, and a small amount of an even higher-grade pattern. By convention, the Gleason score only uses the two most common patterns. So if your cancer is mostly Pattern 3, with some Pattern 4, and a small focus of Pattern 5, the score on paper reads “3+4=7.”

That sounds fine — until you realize the report has hidden the most aggressive component. To prevent this, modern reporting standards require pathologists to name any tertiary Pattern 5 separately, typically described as “Pattern 5 present, less than 5% of total cancer.” Even a small amount of Pattern 5 worsens prognosis enough that the cancer is generally treated as a Grade Group 4 or 5 lesion regardless of the headline number[2]. If your report mentions any Pattern 5 at all, that detail belongs at the top of the conversation with your urologist, not buried in the small print.

How Grade Group Connects to Treatment Decisions

Your Grade Group is one input among several — PSA level, MRI findings, clinical stage, number of positive cores, and the percentage of each core involved all contribute. But the Grade Group sets the framework. The 2024 AUA/ASTRO/SUO guideline lays out the management defaults as follows[7]:

• Grade Group 1 (Gleason 6): Active surveillance is the preferred initial approach for nearly all men. Definitive treatment is reasonable only in selected cases (younger age, large-volume disease, family history).
• Grade Group 2 (Gleason 3+4): Active surveillance is appropriate for men with favorable features — low PSA density, limited cancer volume, no cribriform Pattern 4. Definitive treatment is equally reasonable.
• Grade Group 3 (Gleason 4+3): Treatment is usually recommended — radical prostatectomy or radiation therapy with or without short-term hormonal therapy.
• Grade Group 4 (Gleason 8): Definitive treatment. Often radiation plus 18–24 months of hormonal therapy, or radical prostatectomy with consideration of adjuvant treatment.
• Grade Group 5 (Gleason 9–10): Aggressive multimodal treatment. Radiation plus 24–36 months of hormonal therapy is a common pathway. Surgery is appropriate for selected men, often with adjuvant therapy.

For a more detailed breakdown of when surveillance is the right answer rather than immediate treatment, see our guide to active surveillance for prostate cancer. The key thing to internalize: a Grade Group 1 result is not a directive to do nothing. It is a directive to monitor carefully on a defined schedule — PSA every 6 months, MRI annually, repeat biopsy at intervals — so that any progression is caught early.

What Else on the Report Matters

The Gleason score and Grade Group are the headlines. But a complete biopsy report contains other details that change management. When you read your report, look for these:

• Number of positive cores out of total taken. A standard transrectal biopsy takes 10–14 cores. One positive out of 12 is a very different finding from eight positive out of 12.
• Percentage of cancer in each positive core. A core with 5% cancer involvement is treated differently from a core with 80% involvement, even at the same Grade Group.
• Maximum cancer length per core, in millimeters. This adds nuance to the percentage and is now standard reporting.
• Perineural invasion. Cancer cells tracking along a nerve. Not as ominous as it sounds, but worth noting and discussing.
• Cribriform Pattern 4. If present, should be explicitly stated. Cribriform is a more aggressive subtype of Pattern 4 and can disqualify a man from active surveillance.
• Intraductal carcinoma. Cancer cells growing within prostatic ducts. Strongly associated with aggressive disease and a reason to escalate treatment.
• The biopsy approach used. A transperineal or MRI-targeted biopsy generally samples the prostate more thoroughly than a standard transrectal systematic biopsy. The 2024 AUA guidelines now favor transperineal approaches for many men[10].

If anything on your report seems ambiguous or contradictory, asking for a second pathology opinion is not paranoid — it is sometimes the right call. Studies of expert pathology re-review have shown that the Grade Group changes in roughly 15–20% of cases when read by a dedicated genitourinary pathologist, often shifting men out of (or into) active surveillance eligibility[11]. For high-stakes decisions — Grade Group 1 versus 2, or 2 versus 3 — that is worth knowing.

Putting Your Result Into Context

If you have not had your biopsy yet but you are anticipating one, our guide to prostate biopsy preparation and recovery walks through what the procedure actually involves and how to minimize discomfort and infection risk. If your PSA is what put you on this path, our explainer on PSA results in the 4 to 10 ng/mL grey zone covers when a borderline PSA actually warrants a biopsy versus repeat testing or imaging.

For men weighing whether immediate treatment or surveillance is the right path, you can model your individual risk using our free prostate cancer risk calculator, which combines PSA, Grade Group, clinical stage, and other variables into a pre-treatment risk tier. A separate Gleason score risk interpreter walks through what your specific Grade Group means in practical terms — including likely follow-up schedule and treatment options.

The wider context matters too. Prostate cancer is one of several men’s cancers where early detection meaningfully changes outcomes. If you are reading this because a biopsy result has shifted your awareness of cancer risk generally, our guides to testicular self-examination and the broader men’s health checklist for men over 40 cover the wider screening picture.

Questions Patients Ask Me About Gleason Scores

Dr. Muhammad Khalid

MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · CHPE · CRSM · IMC #539472

Specialist urologist with 11+ years of clinical experience across tertiary teaching hospitals. Trained at Lady Reading Hospital and Khyber Teaching Hospital, Peshawar. Author of 5 peer-reviewed international publications in Cureus, WJSA, and AJBS. Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery. Full profile →

This article is for educational purposes only and does not constitute medical advice. Always consult your physician or urologist for diagnosis and treatment decisions specific to your condition.